



# The role of surgical therapy in the management of premature ejaculation: a narrative review

Hamed Ambusaidi<sup>1,2^</sup>, Muaath Alshuaibi<sup>1,3</sup>, Ahmed S. Zugail<sup>1,4</sup>, Sebastien Beley<sup>1</sup>

<sup>1</sup>Department of Urology, Clinique Turin, Group Almaviva, Paris, France; <sup>2</sup>Department of Urology, Royal Hospital, Muscat, Oman; <sup>3</sup>Department of Urology, Faculty of Medicine, University of Ha'il, Ha'il, Saudi Arabia; <sup>4</sup>Department of Urology, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia

**Contributions:** (I) Conception and design: All authors; (II) Administrative support: H Ambusaidi, M Alshuaibi; (III) Provision of study materials or patients: H Ambusaidi, M Alshuaibi; (IV) Collection and assembly of data: H Ambusaidi, M Alshuaibi; (V) Data analysis and interpretation: H Ambusaidi, AS Zugail; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Hamed Ambusaidi, MD. Department of Urology, Clinique Turin, Group Almaviva, 5 rue de Turin, Paris 75008, France; Department of Urology, Royal Hospital, Muscat, Oman. Email: hamed\_8@hotmail.com.

**Background and Objective:** Premature ejaculation (PE) is a common sexual disorder among male adults and negatively impacts a man's sexual life. Currently, the mainstay treatment of PE is still medical therapy which has drawbacks among patients as a consequence of side effects. Despite the new definitions, the evolution of medical therapy, and the consensus for the management of PE, it remains challenging to treat for many clinicians especially when medical treatment fails. However, the International Society for Sexual Medicine (ISSM) and the American Urological Association (AUA) guidelines ignored surgical therapy due to conflicting medical reports and doubts about the safety of surgical management. This article discusses the surgical management of PE based on recent guidelines, reviews, and evolving techniques.

**Methods:** We reviewed the literature using PubMed and searched for the following keywords: premature ejaculation, selective dorsal neurectomy, hyaluronic acid, dorsal nerve neuromodulation, cryo-ablation of the dorsal nerve and inner condom technique until May 2023. Seventeen studies were found.

**Key Content and Findings:** Even though the widespread use of many surgical modalities in Asia such as glans penis augmentation (GPA) using hyaluronic acid (HA) selective dorsal neurectomy (SDN), cryo-ablation of the dorsal nerve, neuromodulation of the dorsal nerve (NMDN), and circumcision are still considered as controversial for the guidelines.

**Conclusions:** The mainstay treatment of PE is still pharmaceutical. However, the current body of evidence on surgical treatments for PE is limited. Men considering surgical therapy for PE should be counseled well for the risks and benefits as there may be chronic disabilities. Further, well-designed trials are needed to establish safety and efficacy for the surgical treatment.

**Keywords:** Premature ejaculation (PE); selective dorsal neurectomy (SDN); hyaluronic acid (HA); dorsal nerve neuromodulation

Submitted Apr 19, 2023. Accepted for publication Sep 15, 2023. Published online Oct 24, 2023.

doi: 10.21037/tau-23-240

**View this article at:** <https://dx.doi.org/10.21037/tau-23-240>

<sup>^</sup> ORCID: 0000-0002-2399-3119.

## 1 Introduction

2 Premature ejaculation (PE) the most common sexual disorder  
 3 among males. Some studies estimated around 25–40% of  
 4 men suffer from PE at any point in their lives (1-3). PE was  
 5 first reported in the medical literature in 1887 (4). In 2014,  
 6 the International Society for Sexual Medicine (ISSM) defines  
 7 PE as ejaculation that always or nearly always occurs prior  
 8 to or within about 1 minute of vaginal penetration from the  
 9 first sexual experience (lifelong PE) or a clinically significant  
 10 and bothersome reduction in latency time, often to about  
 11 3 minutes or less (acquired PE) (5). Recently, the American  
 12 Urological Association (AUA) and the Sexual Medicine  
 13 Society of North America (SMSNA) guidelines have  
 14 made a notable adjustment to the definition of ejaculation  
 15 latency time (ELT), extending it from 1 to 2 minutes.  
 16 This modification was implemented due to the recognition  
 17 that approximately 20% of men seeking treatment for  
 18 distressing PE actually have an ELT exceeding 2 minutes (6).  
 19 Furthermore, the cause of PE is multifactorial between  
 20 physiology and psychology.

21 The evaluation of the patients suffering from PE  
 22 includes complete medical and psycho-sexual history. In  
 23 addition, intravaginal ejaculatory latency time (IELT)  
 24 can be used to assess patients with PE (7). This sexual  
 25 dysfunction negatively impacts men's sexual health and their  
 26 quality of life. Currently, available therapies for PE include  
 27 behavioral, pharmacological, and surgical therapies. Among  
 28 these pharmacological treatments, selective serotonin  
 29 reuptake inhibitors (SSRI) are considered to be the first-  
 30 line treatment in the management of PE and seem to be the  
 31 most effective (8). However, this type of medical treatment  
 32 can have some side effects, including nausea, vomiting,  
 33 diarrhea, headache, and dizziness, which is seen in 60% of  
 34 patients using dapoxetine (9). Lack of efficacy and compliance  
 35 to the medical therapy is a changeling for many patients  
 36 because of the side effects (10). Despite the presence of  
 37 updated guidelines and the availability of pharmacological  
 38 treatments, the management of PE continues to pose  
 39 challenges for many clinicians. Consequently, surgical  
 40 treatment remains a viable option for individuals who do  
 41 not respond to medical interventions or for patients who  
 42 desire a permanent solution (11).

43 The guidelines of the ISSM of 2014, don't include  
 44 surgical therapies for PE because of their invasiveness  
 45 and the possible permanent complications (12). Surgical  
 46 therapies such as glans penis augmentation (GPA) using as  
 47 hyaluronic acid (HA), selective dorsal neurectomy (SDN),  
 48 cryo-ablation of the dorsal nerve, neuromodulation of dorsal

nerve, and circumcision are widely practiced in Asia (13). 50  
 As each patient of PE can respond differently and may 51  
 experience variable side effects to the pharmacological 52  
 treatment, clinicians must consider all other therapeutic 53  
 modalities when medical treatment fails (14). This article will 54  
 discuss the efficacy and safety of the surgical management 55  
 of PE based on recent guidelines, reviews, and evolving 56  
 techniques. We present this article in accordance with the 57  
 Narrative Review reporting checklist (available at <https://tau.amegroups.com/article/view/10.21037/tau-23-240/rc>). 58  
 59  
 60  
 61

## Methods

62 We conducted the search in the PubMed database using  
 63 the keywords: premature ejaculation, selective dorsal  
 64 neurectomy, hyaluronic acid, dorsal nerve neuromodulation,  
 65 cryo-ablation of the dorsal nerve and inner condom  
 66 technique until May 2023. Eighty-eight records were  
 67 identified. Comments and reports are excluded (N=15).  
 68 The full texts that are not related to the topic are excluded  
 69 (N=56). Full-text original articles of systematic review meta-  
 70 analysis, randomized clinical trials, and prospective studies  
 71 in English on the surgical treatment of PE were retrieved  
 72 (N=17) (*Figure 1*). Author information, year of publication,  
 73 number of participants, follow-up period, IELT, and  
 74 complications were collected from eligible studies (*Table 1*).  
 75  
 76  
 77


## *Surgical methods*

78 Currently, the main surgical approaches for the management  
 79 of PE include: (I) dorsal nerve neurectomy (DNN); (II)  
 80 GPA using HA; (III) circumcision; (IV) inner condom  
 81 technique (*Table 2*) (15-29). Interventional procedures are  
 82 also possible such as computed tomography (CT)-guided  
 83 cryoablation of dorsal nerve ablation and neuromodulation  
 84 of the dorsal nerve (NMDN) (*Table 2*) (30,31). Despite  
 85 the surgical interventions are commonly used in Asia, the  
 86 guidelines do not recommend any type of intervention for PE  
 87 because of the absence of long-term efficacy and safety (13).  
 88  
 89  
 90

## Discussion

### *SDN*

91 SDN is commonly used in Asia, especially in Korea. A  
 92 survey conducted in 2013 by Yang *et al.* stated that 73%  
 93 of Korean urologists have an experience with SDN while  
 94 around 96% of the patients who undergone SDN were  
 95 satisfied (32). In 2012, Zhang *et al.* (15) published that  
 96  
 97  
 98



**Figure 1** Flowchart describing searching methods.

**Table 1** The search strategy summary

Items	Specification
Date of search	February 2023 to May 2023
Databases and other sources searched	PubMed
Search terms	Premature ejaculation, selective dorsal neurectomy, hyaluronic acid, dorsal nerve neuromodulation, cryo-ablation of the dorsal nerve and inner condom technique
Timeframe	No limitation on publication year
Inclusion and exclusion criteria	Inclusion criteria: original articles of systematic review meta-analysis, randomized clinical trials and prospective studies, retrospective, review articles in English Exclusion criteria: comments, case reports
Selection process	The selection process was conducted by Hamed Ambusaidi, Muaath Alshuaibi and independently. The author involved in the process individually screened the articles based on predefined inclusion and exclusion criteria. Any discrepancies or uncertainties were resolved through discussions and consensus among the authors in the review

99 SDN is effective and safe based on a randomized controlled  
 100 trial (RCT) that included 32 SDN and 46 patients who had  
 101 circumcision. The SDN group had an IELT of 1.1 minutes  
 102 preoperatively, which increased to 3.8 minutes post-  
 103 operatively ( $P < 0.01$ ), on the contrary, the circumcision  
 104 group did not show any improvement in the IELT ( $P > 0.005$ ).  
 105 Postoperatively, no complications were reported such as  
 106 wound paraesthesia or infection (15). Liu *et al.* reported that  
 107 anatomic basis SDN is effective in increasing IELT in those  
 108 with lifelong PE ( $0.6 \pm 0.2$  to  $4.2 \pm 3.4$  minutes) and shared  
 109 the same opinion as Zhang *et al.* that SDN is safe and has  
 110 low complication rates (16).

111 Recently an interesting RCT was published by Tang *et al.*

in 2023 (17), in this study, 120 patients with primary 112  
 premature ejaculation (PPE) were operated with SDN. The 113  
 study evaluated the use of intraoperative neurophysiological 114  
 monitoring (IONM) for penile sensory-evoked potential. In 115  
 the IONM group ( $n = 55$ ), the SDN technique was found to 116  
 be significantly effective for 35 patients (63.6%) in achieving 117  
 an IELT of  $\geq 300$  seconds, effective for 17 patients (30.9%) 118  
 with an IELT  $\geq 120$  and  $< 300$  seconds, and ineffective for 119  
 3 patients (5.5%) with an IELT  $< 120$  seconds. On the other 120  
 hand, in the non-IONM group ( $n = 53$ ), the SDN technique 121  
 was significantly effective for 18 patients (34.0%) with 122  
 an IELT  $\geq 300$  seconds, effective for 31 patients (58.5%) 123  
 with an IELT  $\geq 120$  and  $< 300$  seconds, and ineffective 124

**Table 2** Various studies showing surgical management of premature ejaculation

Modality	Study	Methods	Sample size	Outcome (IELT)	Strength	Complication	Limitations
SDN	Zhang <i>et al.</i> , 2012 (15)	RCT	32 SDN 46 circ	Mean SDN (1.1 to 3.8 min), P<0.001 Mean circ (1.2 to 1.5 min), P>0.05	Evaluation of sexual function by BMFSI	No post-op wound pain	No long-term data, small sample single center
	Liu <i>et al.</i> , 2019 (16)	RCT	48 SDN 46 circ	SDN (0.65±0.26 to 4.29±3.42 min) Circ (0.62±0.22 to 0.82±0.43 min)	RCT Full anatomic comparison based on both the number of branches of the dorsal penile nerve and the effect	No significant difference was found in the abnormal sensation in the glans and retardation of ejaculation between the two groups None of the patients experienced permanent glans numbness, wound infection, or hematoma	Cannot determine how many dorsal nerves should be selectively resected for each person to achieve optimal IELT prolongation Single center
	Tang <i>et al.</i> , 2023 (17)	RCT	120 patients	SDN-non IONM median (1 to 4.7 min) SDN-INOM median (0.8 to 4.93 min)	Classification of patients according to neuro-physiological test results Utilizing IONM to minimize irreversible damage to neural tissue Determine how many dorsal nerves must be selectively resected for each individual in order to obtain optimal IELT elongation Maximum resection of nerves is respected by leaving one nerve on each side	12 patients with penile sensory abnormalities (4 patients in the IONM group and 8 patients in the non-IONM group) and 3 patients with mild erectile dysfunction (all in the non-IONM group), P=0.043	Unicentric Longer operative time
GPA using as HA	Kwak <i>et al.</i> , 2008 (18)	Prospective observational study	25 SDN	Mean baseline IELT increased from 1.5 to 4 min	–	5% of patient had numbness	Not RCT, single center, small sample size
	Kim <i>et al.</i> , 2004 (19)	Prospective study	Group I (dorsal neurectomy; n=25) Group II (dorsal neurectomy with HA; n=49) Group III (HA; n=65)	IELT showed no difference between the groups, while at 6 min increased in all groups (group II > III > I)	Patient & partner sexual satisfaction at 6 min increased – sig in all groups (group II > III > I)	–	Not RCT, single center
	Alahwany <i>et al.</i> , 2019 (20)	RCT	Groups: control (saline: n=15); Treatment (HA: n=15) Injection dose: HA (25 mg HA in 2 mL of saline)	Mean baseline IELT: 34 s; 1-month post-op: 120 s; 3-month post-op: 105.5 s; 6-month post-op: 85 s; 9-month post-op: 45 s	RCT with cross over	Complications: At 1-week follow-up, 6/30 patients (20%) had adverse effects, including local discomfort, ecchymosis, local papule. All adverse effects were resolved at 1-month follow-up	Single center, small simple
	Ahn <i>et al.</i> , 2022 (21)	RCT multicenter trial	64 patients	IELT (5.36±3.51 to 7.86±4.73 min)	Patient and partner satisfaction was significant	Inflammation and pain that disappeared in 6.3% of the patients	Single center, small simple
	Shebl <i>et al.</i> , 2021 (22)	RCT	83 patients	Baseline (44.8±8.84 s) 1-month post-op: 277±123.86 s 3-month post-op: 305.14±125.36 s 6-month post-op: 242.97±132.75 s	–	Adverse effects: pain, bruising which are disappeared	Single center, small simple
	Sakr <i>et al.</i> , 2023 (23)	Prospective	30 patients	IELT (37.83±11.01 s at baseline to 323.03±42.06, 281.07±41.05, 241.03±43.09 and 235.6±41.87 s after 1, 3, 6 and 12 months)	–	Adverse effects: 3 patients with discomfort, 2 patients with bullae, and 1 patient with ecchymosis disappeared	Single center, not randomized, small sample

**Table 2** (continued)

Table 2 (continued)

Modality	Study	Methods	Sample size	Outcome (IELT)	Strength	Complication	Limitations
	Littara <i>et al.</i> , 2013 (24)	RCT	110 patients	Baseline pre-op: 88.34±3.14 s 6-month post-op: 293.14±8.16 s	Patient & partner sexual satisfaction increased at 6 min compared to baseline (1 to 5 min)	Not applicable	Single center
	Perri <i>et al.</i> , 2022 (25)	Pilot study	31 patients	Baselines (mean): 38.65 s 30 days: 72.24 s 60 days: 63.75 s 90 days: 41.24 s	Injection only one at the frenulum, which is a very sensitive area of the glans	Not applicable	Single center
	Abdallah <i>et al.</i> , 2012 (26)	RCT	60 patients	1 month (2.12±1.16 to 7.71±7.86 s)	Multicentric	Not applicable	Single center
Circumcision	Tian <i>et al.</i> , 2013 (27)	Systematic review meta-analysis	10 studies	No differences in IELT between the circumcised men and controls	–	No difference in adverse effects between the circumcised men and controls	Low quality studies
	Yang <i>et al.</i> , 2018 (28)	Systematic review meta-analysis	12 studies	No differences in IELT between the circumcised men and controls	–	–	–
Inner condom technique	Wang <i>et al.</i> , 2019 (29)	Prospective	20 patients	Mean pre-op IELT: 0.67 min (range, 0.18–1.1 min) Mean post-op IELT: 2.37 min (range, 0.82–8.4 min)	No nerve resection	No complications reported	Small sample, unicentric, not randomized, invasive and use of homologous material
Neuromodulation of dorsal nerve using pulsed radiofrequency	Basal <i>et al.</i> , 2010 (30)	Prospective	15 patients	IELT: 9.8 (1–49.5) s Median post-op: 119.9 (71.2–239.9) s	Minimally invasive	No numbness, paresthesia, pain, neuroma formation, or erectile dysfunction	Unicentric, small sample, not randomized
Cryo-ablation of dorsal nerves	David Prologo <i>et al.</i> , 2013 (31)	Prospective observational study	24 patients with PE	IELT day 7: 256±104 s (n=11; P=0.241) IELT at 3 months: 182.5±87.8 s (n=6; P=0.0342) IELT at 6 months: 182.5±27.6 s (n=23; P<0.0001) IELT at 1 year: 140.9±83.6 s (n=22; P<0.001)	Unilateral ablation	No complication	Not RCT, small sample, single center

IELT, intravaginal ejaculatory latency time; SDN, selective dorsal neurectomy; Circ, circumcision; RCT, randomized controlled trial; BMFSI, brief male sexual functioning inventory; post-op, postoperative; IONM, intraoperative neurophysiological monitoring; HA, hyaluronic acid; pre-op, preoperative; PE, premature ejaculation.

for 4 patients (7.5%) with an IELT <120 seconds. The clinical efficacy of the SDN technique was significantly better in the IONM group compared to the non-IONM group (P=0.004). Regarding complications, fifteen patients experienced adverse effects, including penile paraesthesia, which involved decreased sensation or varying degrees of numbness or pain, and decreased erectile function. Among these, 12 patients had penile sensory abnormalities (4 patients in the IONM group and 8 patients in the non-IONM group), and 3 patients in the non-IONM group had mild erectile dysfunction (ED). The difference in complications between the two groups was found to be significant (P=0.043) and patients with IONM were significantly more satisfied with SDN than those in the non-IONM (17).

Despite the promising results of SDN in previous studies, concerns were raised against this therapy because of possible ED and post-operative paresthesia (18). The studies conducted by Zhang *et al.* and Liu *et al.* were conducted at a single center and had limited sample sizes. These studies faced notable limitations in terms of safety concerns, particularly in determining the optimal number of dorsal nerves to be resected to achieve effective prolongation of IELT while avoiding serious complications such as delayed ejaculation, penile paraesthesia, and ED. On the other hand, the study by Tang *et al.* reported a significant increase in ED within the non-IONM group, which provides supporting evidence for Anaissie *et al.*'s that SDN is unsafe (13,15-17). Consequently, far in the West the North American and European associations were against SDN (13). As conducted by Tang *et al.*, IONM is needed at least to be selective and determine how many should be resected but this is technically difficult to apply intraoperatively and costly.

#### 160 **GPA using HA**

161 HA is a glycosaminoglycan that finds extensive application  
162 in the medical field due to its ability to inhibit the synthesis  
163 of pro-inflammatory proteins (33). Existing evidence  
164 regarding the use of HA in uro-andrological conditions  
165 indicates its potential benefits. Studies have shown that  
166 HA can alleviate the acute painful phase associated with  
167 Peyronie's disease (34-36) and reduce the frequency of  
168 recurrent urinary infection episodes (37). Additionally, HA  
169 has been reported to improve pain symptoms and enhance  
170 the quality of life in patients with interstitial cystitis (38).  
171 The concept behind this technique is the injection of HA  
172

gel into the glans of the penis to create a physical boundary  
between the hypersensitive dorsal nerves and the outside  
ambiance. The study by Kim *et al.* was one of the first to  
study the effect of the HA gel on the glans (19). Included  
139 patients, divided into 3 groups: (I) DNN group  
(N=25); (II) DNN with HA gel group (N=49); and (III)  
HA gel group (N=65). Ejaculation time at the assessment  
found that preoperative ejaculation times were 89.2±40.29,  
101.54±59.42, and 96.5±52.32 seconds in Groups I, II, and  
III, respectively. DNN group with HA gel was significantly  
longer than the other two groups at 6 months (235.6±58.6,  
324.24±107.58 and 281.9±93.2 seconds in Groups I, II  
and III, respectively (P<0.01). Patient and partner sexual  
satisfaction at 6 months increased significantly in all groups  
(group II > III > I). The previous results suggest that HA  
gel is effective. Six- and 12-month follow-ups revealed the  
effectivity of the HA gel. In contrast to the DNN group,  
no complications were found in the HA gel group (19).  
Alahwany *et al.* (20) in 2019 conducted the first RCT in  
including 30 patients (Control saline group n=15, HA gel  
group n=15). The IELT at 3-, 6-, and 9-month intervals  
in both groups found significant improvement after HA  
in comparison with saline across the follow-up periods  
(P=0.001). The drawback of the study of Alahwany *et al.* is  
that it has a small sample of patients and was a single-center  
study. Regarding the complications, during the 1-week  
follow-up, 6 out of 30 patients (20%) experienced adverse  
effects such as local discomfort, ecchymosis, and local  
papule. However, all of these adverse effects were resolved  
by the 1-month follow-up period (20). Similar findings were  
reported in studies by Ahn *et al.*, Shebl *et al.*, and Sakr *et al.*,  
showing that all adverse effects were resolved by the 1-month  
follow-up (21-23). Many studies have shown that HA is  
effective and safe and support the findings of Kim *et al.* and  
Alahwany *et al.* (24-26) (Table 2).

Moreover, the studies conducted by Kim *et al.*, Littara *et al.*,  
and Abdallah *et al.* consistently demonstrated a significant  
increase in patient and partner satisfaction at 6 months  
(19,24,26). We would share the same opinion as Anaissie  
*et al.* to consider HA gel as a therapeutic option for lifelong  
PE, large and multicentric double-blinded RCTs are  
required to prove the efficacy and safety.

#### 173 **Circumcision**

Circumcision has been one of the most common surgical  
interventions in the world for decades for medical, religious,  
cultural, social, and several other reasons (39). The prepuce

(foreskin) is rich in nerve fibers that account for the hypersensitivity of the human foreskin and its function as erogenous tissue (40). Some studies have shown an increase in IELT from 64 to 731 seconds and a reduction in PE incidence from 32% to 14% (41-43). In two systematic meta-analyses investigating the effects of circumcision on male sexual function after the intervention. Overall, there was no difference between circumcised and uncircumcised men concerning PE, IELT, ED, or pain during intercourse (27,28). These findings suggest that male circumcision is not an effective modality in patients with lifelong PE.

232  
233

### Experimental treatments

234  
235  
236

#### Neuromodulation of dorsal nerve and cryo-ablation of the dorsal nerve

Neuromodulation is safe and effective in urology for urinary incontinence associated with bladder hyperactivity (44). To date, the evidence for the treatment of PE based on NMDN is weak as only low-quality studies have been conducted (Table 2) (30). Randomized control studies are necessary to verify the effectiveness and safety of the previous report. As with the earlier procedure, the cryoablation of the dorsal nerve is still experimental. David Prologo *et al.* found promising results in the unilateral removal of the dorsal nerve (Table 2), but the study was a small specimen, unicentric, and was not randomized (31).

248

#### Inner condom technique

This innovative and experimental surgical technique utilizing an inner condom was first introduced by Wang *et al.* in 2019. The procedure involved the insertion of acellular dermal matrix (ADM), a biomaterial derived from human skin, beneath the buck's fascia under local anesthesia. In this particular study, a total of 20 men diagnosed with PPE, with an average IELT of 0.67 minutes, underwent this intervention. Following the procedure, the average IELT significantly increased to 2.3 minutes (ranging from 0.82 to 8.4 minutes) (P=0.009) (29). The surgical technique employed in this study is characterized by its invasiveness, and the methodology utilized is limited by being a single-center study with a small sample size. Additionally, the study lacks randomization, which further necessitates caution in interpreting the results.

265  
266

### Limitations

267  
268

In this narrative review, we recognize that surgical

interventions for the management of PE are common in Asia, and therefore, relevant studies conducted in non-English languages may have been excluded. Furthermore, the variety of surgical procedures, protocols, and follow-up periods may have led to bias in this review.

## Conclusions

The mainstay treatment of PE is still pharmaceutical. Among these surgical approaches, HA is minimally invasive and promising in terms of efficacy and safety. However, the current body of evidence on surgical treatments for PE is limited. Men considering surgical therapy for PE should be counseled well for the risks and benefits as there may be chronic disabilities. Further, well-designed trials are needed to establish safety and efficacy for the Surgical treatment.

## Acknowledgments

*Funding:* None.

## Footnote

*Reporting Checklist:* The authors have completed the Narrative Review reporting checklist. Available at <https://tau.amegroups.com/article/view/10.21037/tau-23-240/rc>

*Peer Review File:* Available at <https://tau.amegroups.com/article/view/10.21037/tau-23-240/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://tau.amegroups.com/article/view/10.21037/tau-23-240/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

317 See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

318

319

## References

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

1. Hanafy S, Hamed AM, Hilmy Samy MS. Prevalence of premature ejaculation and its impact on the quality of life: Results from a sample of Egyptian patients. *Andrologia* 2019;51:e13298.
2. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *Int J Impot Res* 2005;17:39-57.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. *JAMA* 1999;281:537-44.
4. Parnham A, Serefoglu EC. Classification and definition of premature ejaculation. *Transl Androl Urol* 2016;5:416-23.
5. Saleh R, Majzoub A, Abu El-Hamd M. An update on the treatment of premature ejaculation: A systematic review. *Arab J Urol* 2021;19:281-302.
6. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. *J Urol* 2022;207:504-12.
7. Gillman N, Gillman M. Premature Ejaculation: Aetiology and Treatment Strategies. *Med Sci (Basel)* 2019;7:102.
8. Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. *Int Braz J Urol* 2019;45:1209-15.
9. Russo A, Capogrosso P, Ventimiglia E, et al. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. *Int J Clin Pract* 2016;70:723-33.
10. Shindel A, Nelson C, Brandes S. Urologist practice patterns in the management of premature ejaculation: a nationwide survey. *J Sex Med* 2008;5:199-205.
11. Moon du G. Is there a place for surgical treatment of premature ejaculation? *Transl Androl Urol* 2016;5:502-7.
12. Althof SE, McMahon CG, Waldinger MD, et al. An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). *Sex Med* 2014;2:60-90.
13. Anaissie J, Yafi FA, Hellstrom WJ. Surgery is not indicated for the treatment of premature ejaculation. *Transl Androl Urol* 2016;5:607-12.
14. Serefoglu EC, Saitz TR, Trost L, et al. Premature ejaculation: do we have effective therapy? *Transl Androl Urol* 2013;2:45-53.
15. Zhang GX, Yu LP, Bai WJ, et al. Selective resection of dorsal nerves of penis for premature ejaculation. *Int J Androl* 2012;35:873-9.
16. Liu Q, Li S, Zhang Y, et al. Anatomic Basis and Clinical Effect of Selective Dorsal Neurectomy for Patients with Lifelong Premature Ejaculation: A Randomized Controlled Trial. *J Sex Med* 2019;16:522-30.
17. Tang QL, Song T, Han YF, et al. The application of intraoperative neurophysiological monitoring in selective dorsal neurotomy for primary premature ejaculation: a prospective single-center study. *Asian J Androl* 2023;25:137-42.
18. Kwak TI, Jin MH, Kim JJ, et al. Long-term effects of glans penis augmentation using injectable hyaluronic acid gel for premature ejaculation. *Int J Impot Res* 2008;20:425-8.
19. Kim JJ, Kwak TI, Jeon BG, et al. Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. *Int J Impot Res* 2004;16:547-51.
20. Alahwany A, Ragab MW, Zaghoul A, et al. Hyaluronic acid injection in glans penis for treatment of premature ejaculation: a randomized controlled cross-over study. *Int J Impot Res* 2019;31:348-55.
21. Ahn ST, Shim JS, Bae WJ, et al. Efficacy and Safety of Penile Girth Enhancement Using Hyaluronic Acid Filler and the Clinical Impact on Ejaculation: A Multi-Center, Patient/Evaluator-Blinded, Randomized Active-Controlled Trial. *World J Mens Health* 2022;40:299-307.
22. Shebl SE, Ali S, Shokr M. Hyaluronic acid injection in the glans penis for the treatment of refractory premature ejaculation: A prospective, controlled study. *Andrologia* 2021;53:e14084.
23. Sakr A, Elgalaly H, Seleem MM, et al. Outcome of hyaluronic acid gel injection in glans penis for treatment of lifelong premature ejaculation: A pilot study. *Arab J Urol* 2022;21:31-5.
24. Littara A, Palmieri B, Rottigni V, et al. A clinical study to assess the effectiveness of a hyaluronic acid-based procedure for treatment of premature ejaculation. *Int J Impot Res* 2013;25:117-20.
25. Perri A, Lofaro D, Iuliano S, et al. Effects of One-Shot Hyaluronic Acid Injection in Lifelong Premature Ejaculation: A Pilot Study. *Endocrines* 2022;3:538-44.
26. Abdallah H, Abdelnasser T, Hosny H, et al. Treatment of premature ejaculation by glans penis augmentation using hyaluronic acid gel: a pilot study. *Andrologia* 2012;44 Suppl 1:650-3.
27. Tian Y, Liu W, Wang JZ, et al. Effects of circumcision on male sexual functions: a systematic review and meta-analysis. *Asian J Androl* 2013;15:662-6.



- 413 28. Yang Y, Wang X, Bai Y, et al. Circumcision does not have  
414 effect on premature ejaculation: A systematic review and  
415 meta-analysis. *Andrologia* 2018. 444
- 416 29. Wang H, Bai M, Zhang HL, et al. Surgical treatment  
417 for primary premature ejaculation with an inner condom  
418 technique. *Medicine (Baltimore)* 2019;98:e14109. 445
- 419 30. Basal S, Goktas S, Ergin A, et al. A novel treatment  
420 modality in patients with premature ejaculation resistant  
421 to conventional methods: the neuromodulation of  
422 dorsal penile nerves by pulsed radiofrequency. *J Androl*  
423 2010;31:126-30. 446
- 424 31. David Prologo J, Snyder LL, Cherullo E, et al.  
425 Percutaneous CT-guided cryoablation of the dorsal penile  
426 nerve for treatment of symptomatic premature ejaculation.  
427 *J Vasc Interv Radiol* 2013;24:214-9. 447
- 428 32. Yang DY, Ko K, Lee WK, et al. Urologist's Practice  
429 Patterns Including Surgical Treatment in the Management  
430 of Premature Ejaculation: A Korean Nationwide Survey.  
431 *World J Mens Health* 2013;31:226-31. 448
- 432 33. Zucchi A, Scropo FI, Capogrosso P, et al. Clinical use  
433 of hyaluronic acid in andrology: A review. *Andrology*  
434 2022;10:42-50. 449
- 435 34. Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic  
436 acid: an innovative treatment for Peyronie's disease. *Int*  
437 *Urol Nephrol* 2015;47:1595-602. 450
- 438 35. Zucchi A, Costantini E, Cai T, et al. Intralesional Injection  
439 of Hyaluronic Acid in Patients Affected With Peyronie's  
440 Disease: Preliminary Results From a Prospective,  
441 Multicenter, Pilot Study. *Sex Med* 2016;4:e83-8. 451
- 442 36. Russo GI, Cacciamani G, Cocci A, et al. Comparative  
443 Effectiveness of Intralesional Therapy for Peyronie's  
444 Disease in Controlled Clinical Studies: A Systematic  
445 Review and Network Meta-Analysis. *J Sex Med*  
446 2019;16:289-99. 452
- 447 37. Goddard JC, Janssen DAW. Intravesical hyaluronic  
448 acid and chondroitin sulfate for recurrent urinary tract  
449 infections: systematic review and meta-analysis. *Int*  
450 *Urogynecol J* 2018;29:933-42. 453
- 451 38. Pyo JS, Cho WJ. Systematic Review and Meta-Analysis  
452 of Intravesical Hyaluronic Acid and Hyaluronic Acid/  
453 Chondroitin Sulfate Instillation for Interstitial Cystitis/  
454 Painful Bladder Syndrome. *Cell Physiol Biochem*  
455 2016;39:1618-25. 455
- 456 39. Cold CJ, Taylor JR. The prepuce. *BJU Int* 1999;83 Suppl  
457 1:34-44. 456
- 458 40. Namavar MR, Robati B. Removal of foreskin remnants in  
459 circumcised adults for treatment of premature ejaculation.  
460 *Urol Ann* 2011;3:87-92. 457
- 461 41. Cortés-González JR, Arratia-Maqueo JA, Martínez-  
462 Montelongo R, et al. Does circumcision affect male's  
463 perception of sexual satisfaction? *Arch Esp Urol*  
464 2009;62:733-6. 458
- 465 42. Gao J, Xu C, Zhang J, et al. Effects of adult male  
466 circumcision on premature ejaculation: results  
467 from a prospective study in China. *Biomed Res Int*  
468 2015;2015:417846. 459
- 469 43. Zhang SJ, Zhao YM, Zheng SG, et al. Correlation  
470 between premature ejaculation and redundant prepuce.  
471 *Zhonghua Nan Ke Xue* 2006;12:225-7. 460
- 472 44. Tilborghs S, De Wachter S. Sacral neuromodulation for  
473 the treatment of overactive bladder: systematic review and  
474 future prospects. *Expert Rev Med Devices* 2022;19:161-87. 461

**Cite this article as:** Ambusaidi H, Alshuaibi M, Zugail AS, Beley S. The role of surgical therapy in the management of premature ejaculation: a narrative review. *Transl Androl Urol* 2023;12(10):1589-1597. doi: 10.21037/tau-23-240